Nature Communications (Jun 2021)
CVnCoV and CV2CoV protect human ACE2 transgenic mice from ancestral B BavPat1 and emerging B.1.351 SARS-CoV-2
- Donata Hoffmann,
- Björn Corleis,
- Susanne Rauch,
- Nicole Roth,
- Janine Mühe,
- Nico Joel Halwe,
- Lorenz Ulrich,
- Charlie Fricke,
- Jacob Schön,
- Anna Kraft,
- Angele Breithaupt,
- Kerstin Wernike,
- Anna Michelitsch,
- Franziska Sick,
- Claudia Wylezich,
- Bernd Hoffmann,
- Moritz Thran,
- Andreas Thess,
- Stefan O. Mueller,
- Thomas C. Mettenleiter,
- Benjamin Petsch,
- Anca Dorhoi,
- Martin Beer
Affiliations
- Donata Hoffmann
- Institute of Diagnostic Virology, Friedrich-Loeffler-Institut
- Björn Corleis
- Institute of Immunology, Friedrich-Loeffler-Institut
- Susanne Rauch
- CureVac AG
- Nicole Roth
- CureVac AG
- Janine Mühe
- CureVac AG
- Nico Joel Halwe
- Institute of Diagnostic Virology, Friedrich-Loeffler-Institut
- Lorenz Ulrich
- Institute of Diagnostic Virology, Friedrich-Loeffler-Institut
- Charlie Fricke
- Institute of Immunology, Friedrich-Loeffler-Institut
- Jacob Schön
- Institute of Diagnostic Virology, Friedrich-Loeffler-Institut
- Anna Kraft
- Institute of Diagnostic Virology, Friedrich-Loeffler-Institut
- Angele Breithaupt
- Department of Experimental Animal Facilities and Biorisk Management, Friedrich-Loeffler-Institut
- Kerstin Wernike
- Institute of Diagnostic Virology, Friedrich-Loeffler-Institut
- Anna Michelitsch
- Institute of Diagnostic Virology, Friedrich-Loeffler-Institut
- Franziska Sick
- Institute of Diagnostic Virology, Friedrich-Loeffler-Institut
- Claudia Wylezich
- Institute of Diagnostic Virology, Friedrich-Loeffler-Institut
- Bernd Hoffmann
- Institute of Diagnostic Virology, Friedrich-Loeffler-Institut
- Moritz Thran
- CureVac AG
- Andreas Thess
- CureVac AG
- Stefan O. Mueller
- CureVac AG
- Thomas C. Mettenleiter
- Friedrich-Loeffler-Institut, Federal Research Institute for Animal Health
- Benjamin Petsch
- CureVac AG
- Anca Dorhoi
- Institute of Immunology, Friedrich-Loeffler-Institut
- Martin Beer
- Institute of Diagnostic Virology, Friedrich-Loeffler-Institut
- DOI
- https://doi.org/10.1038/s41467-021-24339-7
- Journal volume & issue
-
Vol. 12,
no. 1
pp. 1 – 7
Abstract
Emerging SARS-CoV-2 variants with mutations in the spike protein raise concerns regarding vaccine efficacy. Here, the authors show that two spike encoding mRNA vaccines in preclinical and clinical development protect human ACE2 mice from the B.1.351 variant of concern and ancestral B BavPat1.
